New targets for treatment of multiple sclerosis

J Neurol Sci. 2008 Nov 15;274(1-2):1-4. doi: 10.1016/j.jns.2008.06.040. Epub 2008 Sep 3.

Abstract

By studying gene transcripts in active lesions of multiple sclerosis via robotic sequencing and gene chips, as well as studying the very same tissue via proteomics, we have discovered several targets at the tipping points in pathophysiologic pathways controlling relapse and remission in multiple sclerosis. In this Charcot Lecture, I shall focus on osteopontin-the binding partner for alpha4 beta 1 integrin, on alpha B crystallin and on two members of the coagulation cascade tissue factor and the inhibitor of protein C. These four proteins are critical in controlling relapse and remission in MS.

Publication types

  • Review

MeSH terms

  • Blood Coagulation Factors / metabolism
  • Humans
  • Multiple Sclerosis / metabolism*
  • Multiple Sclerosis / therapy*
  • Osteopontin / metabolism
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase Inhibitors / therapeutic use
  • Proteomics / methods
  • alpha-Crystallin B Chain / metabolism

Substances

  • Blood Coagulation Factors
  • Protein Kinase Inhibitors
  • alpha-Crystallin B Chain
  • Osteopontin
  • Protein Kinase C